...
首页> 外文期刊>Science Advances >Molecular subtyping of Alzheimer’s disease using RNA sequencing data reveals novel mechanisms and targets
【24h】

Molecular subtyping of Alzheimer’s disease using RNA sequencing data reveals novel mechanisms and targets

机译:使用RNA测序数据的阿尔茨海默病的分子亚型揭示了新的机制和目标

获取原文

摘要

Alzheimer’s disease (AD), the most common form of dementia, is recognized as a heterogeneous disease with diverse pathophysiologic mechanisms. In this study, we interrogate the molecular heterogeneity of AD by analyzing 1543 transcriptomes across five brain regions in two AD cohorts using an integrative network approach. We identify three major molecular subtypes of AD corresponding to different combinations of multiple dysregulated pathways, such as susceptibility to tau-mediated neurodegeneration, amyloid-β neuroinflammation, synaptic signaling, immune activity, mitochondria organization, and myelination. Multiscale network analysis reveals subtype-specific drivers such as GABRB2 , LRP10 , MSN , PLP1 , and ATP6V1A . We further demonstrate that variations between existing AD mouse models recapitulate a certain degree of subtype heterogeneity, which may partially explain why a vast majority of drugs that succeeded in specific mouse models do not align with generalized human trials across all AD subtypes. Therefore, subtyping patients with AD is a critical step toward precision medicine for this devastating disease.
机译:阿尔茨海默病(AD)是最常见的痴呆形式,被认为是具有多种病理学机制的异质疾病。在这项研究中,我们通过使用综合网络方法分析两个AD队列中的五个脑区的1543转录om来询问AD的分子异质性。我们鉴定了对应于多种呼吸困难途径的不同组合的三种主要分子亚型,例如对Tau介导的神经变性,淀粉样蛋白-β神经炎,突触信号,免疫活性,线粒体组织和髓鞘产生的易感性。多尺度网络分析显示亚型特定驱动程序,如GABRB2,LRP10,MSN,PLP1和ATP6V1A。我们进一步证明现有的AD小鼠模型之间的变化能够概括一定程度的亚型异质性,这可能部分解释为什么绝大多数在特定小鼠模型中成功的药物不与所有AD亚型的广义人类试验对齐。因此,患有AD的亚型患者是对这种破坏性疾病进行精密药的关键步骤。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号